- Home
- TRC vs SLDB Comparison
TRC vs SLDB Comparison
Compare TRC & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- SLDB
- Stock Information
- Founded
- TRC 1843
- SLDB 2013
- Country
- TRC United States
- SLDB United States
- Employees
- TRC N/A
- SLDB N/A
- Industry
- TRC Real Estate
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRC Finance
- SLDB Health Care
- Exchange
- TRC Nasdaq
- SLDB Nasdaq
- Market Cap
- TRC 427.8M
- SLDB 366.2M
- IPO Year
- TRC N/A
- SLDB 2018
- Fundamental
- Price
- TRC $16.56
- SLDB $2.55
- Analyst Decision
- TRC
- SLDB Strong Buy
- Analyst Count
- TRC 0
- SLDB 9
- Target Price
- TRC N/A
- SLDB $15.67
- AVG Volume (30 Days)
- TRC 133.7K
- SLDB 1.2M
- Earning Date
- TRC 05-06-2025
- SLDB 05-14-2025
- Dividend Yield
- TRC N/A
- SLDB N/A
- EPS Growth
- TRC N/A
- SLDB N/A
- EPS
- TRC 0.10
- SLDB N/A
- Revenue
- TRC $41,886,000.00
- SLDB N/A
- Revenue This Year
- TRC $0.64
- SLDB N/A
- Revenue Next Year
- TRC N/A
- SLDB $569.02
- P/E Ratio
- TRC $165.60
- SLDB N/A
- Revenue Growth
- TRC N/A
- SLDB N/A
- 52 Week Low
- TRC $14.71
- SLDB $2.47
- 52 Week High
- TRC $19.82
- SLDB $10.99
- Technical
- Relative Strength Index (RSI)
- TRC 61.63
- SLDB 28.24
- Support Level
- TRC $15.32
- SLDB $2.48
- Resistance Level
- TRC $16.12
- SLDB $2.88
- Average True Range (ATR)
- TRC 0.49
- SLDB 0.33
- MACD
- TRC 0.09
- SLDB -0.06
- Stochastic Oscillator
- TRC 98.06
- SLDB 6.25
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.